Clinical trials: Intestine
Crohn's Disease
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that…
- Trial name
- NCT01150890
- Testing
- Brodalumab
- Where
- 50 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Amgen
Colorectal Cancer
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
Participants with metastatic Colorectal Cancer (mCRC) who have progressed on a prior Anti-epidermal growth factor receptor (EGFR) regimen randomized to receive IMC-A12 monotherapy or combination therapy with cetuximab to assess…
- Trial name
- NCT00503685
- Testing
- IMC-A12, cetuximab
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eli Lilly and Company
Colitis, Ulcerative
BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis
This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are to prove the concept of clinical activity of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active…
- Trial name
- NCT03482635
- Testing
- Spesolimab
- Where
- 54 sites in United States, Austria and 10 more
- Volunteers
- 98 people
- Sponsor
- Boehringer Ingelheim
Irritable Bowel Syndrome
Irritable Bowel Syndrome Hypnotherapy
The primary goal of the study was whether gut focused hypnotherapy, in a group format, was successful in reduction of symptoms in patients with irritable bowel syndrome.
- Trial name
- NCT01248013
- Testing
- gut focused hypnotherapy
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Mind-Body Digestive Center
Ulcerative Colitis, Crohn's Disease
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
This study will evaluate the long-term safety and tolerability of UTTR1147A in participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), enrolling up to 320 participants from the parent studies: Phase…
- Trial name
- NCT03650413
- Testing
- UTTR1147A
- Where
- 57 sites in United States, Bulgaria and 12 more
- Volunteers
- 143 people
- Sponsor
- Genentech, Inc.
Rectal Cancer
BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
The primary goal of this Brown University Oncology Research Group is to determine that a safe dose of BYL719 can be administered with capecitabine and radiation in patients with rectal cancer.
- Trial name
- NCT02550743
- Testing
- BYL719, Capecitabine, Radiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- howard safran
Gynecologic Cancer, Colorectal Cancer
Patient-Centered Intervention to Reduce Cancer Patients' Financial Toxicity
The purpose of this study is to incorporate feedback from cancer patients and providers to adapt, implement, and test an intervention.
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Lung Cancer
- Trial name
- NCT04314284
- Testing
- I Can PIC, Historical control survey, Post-intervention survey (I Can PIC participants)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Washington University School of Medicine
Type 3 Von Willebrand's Disease
Type 3 Von Willebrand International Registries Inhibitor Prospective Study
International Registries and Prospective Study on Type 3 Von Willebrand's Disease (VWD3), aimed to assess number, types and risk factors for bleeding and the efficacy and safety of plasma-derived and/or recombinant Von Willebrand…
- Trial name
- 3WINTERS-IPS (NCT02460458)
- Testing
- Von Willebrand Factor
- Where
- 25 sites in Finland, France and 8 more
- Volunteers
- 265 people
- Sponsor
- Fondazione Angelo Bianchi Bonomi
Ulcerative Colitis
Efficacy and Safety of Oral BT-11 in Ulcerative Colitis
This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter study with an optional open-label extension (OLE) period.
- Trial name
- NCT03861143
- Testing
- BT-11 (440 mg), BT-11 (880 mg)
- Where
- 16 sites in United States, Bosnia and Herzegovina and 3 more
- Volunteers
- 198 people
- Sponsor
- NImmune Biopharma
Ulcerative Colitis
A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
A placebo controlled study of two doses of HMPL-004 in patients with active mild to moderate ulcerative colitis (UC), with a modified Mayo Score 4-10 and an endoscopy subscore of 2-3, taking mesalamine (or equivalent) as a…
- Trial name
- NCT01805791
- Testing
- HMPL-004 1800 mg/day, HMPL-004 2400 mg/day
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Hutchison Medipharma Limited
Gastroschisis
Evaluation of Glycerin Suppositories to Improve Bowel Function in Gastroschisis
Gastroschisis is a congenital defect of the abdominal wall that leads to evisceration of various amounts of the abdominal organs.
- Trial name
- NCT03355326
- Testing
- Glycerin Suppository
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Indiana University
Constipation Predominant Irritable Bowel Syndrome
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
This phase 3, 26-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of one dose of Tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as…
- Trial name
- T3MPO-2 (NCT02686138)
- Testing
- Tenapanor
- Where
- 117 sites in United States
- Volunteers
- 593 people
- Sponsor
- Ardelyx
Dysentery, Diarrhea
Efficacy of Rifaximin in Preventing Campylobacteriosis
This study is a randomized, double-blinded, placebo-controlled, in-patient trial evaluating the prophylactic efficacy of rifaximin against campylobacteriosis following challenge with C. jejuni.
- Conditions
- Dysentery, Diarrhea, Enteric Campylobacteriosis
- Trial name
- NCT02280044
- Testing
- Rifaximin intervention
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Crohn Disease
Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease
Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease, with many of those being young children and adolescents.
- Trial name
- REMODEL (NCT04974099)
- Testing
- RoadMAB precision dashboard, Infliximab precision dosing
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Crohn´s Disease
A Study With Pentasa in Patients With Active Crohn's Disease
The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose and a 4 g evening dose is efficacious in active mild to moderate CD.
- Trial name
- PEACE (NCT00862121)
- Testing
- Pentasa
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 20 people
- Sponsor
- Ferring Pharmaceuticals
Ulcerative Colitis
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.
- Trial name
- NCT03281304
- Testing
- CP-690,500 5 mg, CP-690,550 10 mg
- Where
- 80 sites in United States, Belgium and 18 more
- Volunteers
- 140 people
- Sponsor
- Pfizer
Recurrent Rectal Cancer
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer
The purpose of this trial is to determine the maximum tolerated dose (MTD) of hypofractionated IMPT for the reirradiation of locoregionally recurrent rectal cancer.
- Trial name
- IMPARC (NCT04827732)
- Testing
- Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy, MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Obstructive Defecation Syndrome, Chronic Constipation
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
The primary purpose of this study is to determine how effective and how durable STARR (stapled transanal rectal resection) surgery is in relieving symptoms of intractable constipation associated with obstructive defecation…
- Conditions
- Obstructive Defecation Syndrome, Chronic Constipation, Rectocele, Intussusception
- Trial name
- NCT00256984
- Testing
- Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Ethicon Endo-Surgery
Crohn's Disease
Crohn's Disease Stem Cell Transplantation
Crohn's disease (CD) is a chronic illness, immunologically mediated, probably induced by the exposure of the intestine to an antigen or antigens similar to the intestine, to which immunologic tolerance is lost or a dysregulated…
- Trial name
- NCT00271947
- Testing
- Autologous Stem Cell Transplantation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Crohn's Disease
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease
A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] due to an exacerbation of Crohn's Disease.
- Trial name
- PRECiSE 4 (NCT00160706)
- Testing
- Certolizumab Pegol (CDP870)
- Where
- 141 sites in United States, Australia and 22 more
- Volunteers
- 310 people
- Sponsor
- UCB Pharma SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.